Results

Stroke Model
AAV9-CMVLacZ or AAV1-CMVLacZ was injected into the jugular vein 1 hour after MCAO ( Figure 1A ). Brain samples were collected 5 days later. Infarct region was visualized on Nissl-stained and NeuN antibody-stained sections (Figure 1B Representative images of a X-gal (left) and lectin (middle) costained brain section collected from AAV1-CMVLacZ (B) and AAV9-CMVLacZ (C) vector-injected mice with brain angiogenesis. To visualize both vessels and LacZ expression, lectin-positive vessels were converted to pink in the merged picture (right). Scale bar: 100 μm.
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and Supplementary Figure III) . LacZ expression in the brain was predominantly in the peri-infarct region of AAV9-CMVLacZinjected mice and was very weak in other brain regions (Supplementary Figure VII) . No LacZ expression was detected in the brain of AAV1-CMVLacZ-injected mice, including the peri-infarct region ( Figure 1C ). LacZ expression was detected in the heart and liver of all mice injected with AAV1-CMVLacZ or AAV9-CMVLacZ (Supplementary Figure I) . We then tested if HREs could prevent gene expression in other organs. AAV9-H9LacZ that has 9 copies of HREs controlling LacZ expression 7 was injected into the jugular vein 1 hour after MCAO. LacZ expression was detected only in the peri-infarct region 5 days later ( Figure 1B and 1C) . No significant gene expression was detected in other brain regions or other organs ( Supplementary Figures I and VII) .
The infarct size and the number of CD68 + cells at the periinfarct region were comparable among nonvector-injected and vector-injected mice (Supplementary Figures IV and V) , suggesting that IV-delivered AAV vector did not increase local inflammation and neuronal injury.
Angiogenic Model
Brain focal angiogenesis was induced by stereotactic injection of AAV1-VEGF into the basal ganglia. AAV9-CMVLacZ or AAV1-CMVLacZ was injected into the jugular vein 28 days later. LacZ-positive spots were found predominantly in the angiogenic foci 5 days later in the AAV9-CMVLacZ group, but not in the AAV1-CMVLacZ group ( Figure 2B and 2C). LacZ expression also was detected in the heart and liver of all mice (Supplementary Figure II) .
Discussion
We demonstrated that IV injection of ssAAV9 mediates significant transgene expression in the peri-infarct region of focal ischemic injury and brain angiogenic foci, and that HRE restricted transgene expression in the peri-infarct region. Therefore, ssAAV9 combined with regulated elements can mediate targeted therapeutic gene expression in the brain lesion through noninvasive IV injection.
Active transport mechanism has been suggested in facilitating AAV9 crossing the BBB. 8 In our study, however, higher LacZ expression was detected in the peri-infarct region and angiogenic foci than in other brain regions, suggesting that increased BBB permeability plays an important role. The BBB permeability is increased within 10 minutes after permanent MCAO, and the increase lasts at least 24 hours (Supplementary Figure VI) . 9 ,10 However, we do not know if the expression pattern persists when the vectors are injected at a later stage of MCAO.
Although IV injection of ssAAV9 (5 × 10 11 gcs) infects some cells in the normal brain, the efficiency is much lower than that of scAAV9. 8 We showed that after IV injection, gene expression in the brain is predominantly at the peri-infarct area and angiogenic foci. In summary, we have demonstrated in this study that IV injection of ssAAV9 can deliver therapeutic genes into the brain regions of adult mice where the BBB permeability is increased. More importantly, to reduce systemic side effects, the therapeutic gene expression can be further restricted to the brain lesion by incorporating regulatory elements. ssAAV9, in combination with regulator elements, can be used to design safe and effective gene-based therapies for the treatment of ischemic stroke and brain vascular diseases.
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AAV Vector Production
AAV9-H9LacZ was packaged by Vector Biolabs (Philadelphia, PA). Other vectors were made as previously described 1, 2 using the three plasmid co-transfection system. 3 Two helper plasmids, one with adenoviral VA, E2A, and E4 regions, and the other with the AAV rep and cap genes were co-transfected with AAV plasmids into HEK 293 cells to package the AAV vector. AAV vectors were purified using CsCl 2 centrifugation. Viral titers were determined by dot blot analysis of DNA content and expressed as genome copies (gcs).
Distal Permanent Middle Cerebral Artery Occlusion
Mice were anesthetized via isoflurane inhalation. Under a surgical microscope, a 1-cm incision was made between the right orbit and tragus. A piece of 2 mm 2 skull was removed. The arachnoid was opened, and the middle cerebral artery (MCA) was permanently occluded with electrocoagulation. The temporal muscle was repositioned, and the skin closed. Body temperature was maintained at 37±0.5°C by using a thermal blanket throughout the surgical procedure, and system blood pressure was monitored using tail-cuff system from Visitech Systems (Apex). Surface cerebral blood flow (sCBF) was monitored during MCAO procedure as described below. Mice were excluded from the experiment if sCBF in the ischemic core region measured more than 15% of the baseline.
Stereotactic Injection of AAV Vectors into the Basal Ganglia
Following induction of anesthesia with isoflurane inhalation, the mice were placed in a stereotactic frame with a holder (David Kopf Instruments, Tujunga, CA), and a burr hole was drilled in the pericranium 2 mm lateral to the sagittal suture, 1 mm posterior to the coronal suture, and 3 mm under the cortex. Two µl viral suspension containing 2X10 9 genome copies (gcs) of AAV-VEGF were stereotactically injected into the right basal ganglia at a rate of 0.2 µl per minute using a Hamilton syringe. The needle was withdrawn after 10 min and the wound was closed with a suture.
Intravenous Injection of AAV Vectors
Following induction of anesthesia with isoflurane inhalation, the right jugular vein was exposed and AAV vectors (2 x10 11 , 8 x10 11 , and 1x10 12 gcs) in 200 µL of PBS were injected. The wound was closed with sutures after the injection.
5-bromo-4-chloro-3-indolyl-β-D-galactosidase (X-gal) Staining
X-gal staining was performed as described. Twenty μm coronal sections were fixed in 0.5 % glutaraldehyde for 10 minutes, incubated overnight in X-gal staining solution (5 mmol/L K3Fe (CN)6, 5 mmol/L K4Fe (CN)6, 2 mmol/L MgCl2, 0.01% sodium deoxycholate, and 1 mg/ml X-gal in PBS), and photographed.
Identifying the Infarct Region and Analysis Infarct Size
A series of 20-µm thick coronal sections was obtained. One in every 10 sections was stained with cresyl violet and digitized. After binary imaging, the infarct and the ispilateral hemisphere areas were outlined using Image J software, then measured. The infarct and ispilateral hemisphere volumes were estimated as the sum of each area multiplied by 200 µm. The percentage of infarct volume was determined as the ratio of the infarct volume divided by the ipsilateral volume multiplied by 100.
Identifying the Angiogenic Foci
The angiogenic foci were identified on the lectin-stained sections. The staining was performed using a series of 20-µm-thick coronal sections. Sections were fixed with 100% ethanol at 20°C for 20 minutes, then incubated overnight with fluoresceinlycopersicin esculentum lectin (Vector Lab, Burlingame, CA), 2 g/ml at 4°C.
For X-gal and lectin double staining, we did X-gal staining first, and then lectin staining.
Immunohistochemistry
Brain samples were frozen in dry ice. Twenty µm thick coronal cryostat sections were made on a Leica CM1900 Cryostat (Leica). Sections were stained overnight with antibodies specific to NeuN (1:500, Chemicon, Temecular, CA), CD68 (1:50, AbD Serotec, Raleigh, NC) and β-gal (1:500, Abcam Inc., Cambridge, MA). Sections were incubated for 90 min with secondary antibodies Alexa 594 anti-mouse IgG and Alexa 488 anti-rabbit IgG (1:500 dilution; Invitrogen, Carlsbad, CA), and coverslipped with Vectashield mounting medium with 4'-6-diamidino-2-phenylinidole (DAPI) (Vector Laboratory) to label cell nuclei. Sections were imaged with a Leica DMLS fluorescent microscope with Spot Insight Software (Diagnostic Instruments, Inc., Sterling Heights, MI). Two sections 200 µm apart (between bregma 1.2 to 1.4 mm) were selected from each brain for quantification of the CD68 positive cells. Two pictures were taken under 20X objective from each section in the peri-infarct region shown in Supplemental Figure S6 . The CD68 positive cells were quantified using image J (NIH, USA).
Evans Blue Leakage Analysis
We used a method modified from previously described Evans blue assay. 4 Before the animals were sacrificed, 4 ml/kg of 2% Evans blue (Sigma) in normal saline were injected into the left jugular vein of anesthetized animals. The animals were perfused with saline 60 minutes later, followed by 1% paraformaldehyde in 50 mmol/L citrate buffer. Photos were taken after the
